Indication name:
Primary Sclerosing
Cholangitis (PSC) - Thelansis
Epidemiology study indicates incidnece of PSC 1 person per each 100,000 in the
general population in the United States or Europe.
Competitive landscape of PSC
includes country specific approved as well as pipeline therapies. Any asset/
product specific designation or review and Accelerated Approval are being
tracked and supplemented with analyst commentary.
KOLs insights of PSC across 8 MM
market from center of Excellence/ Public/ Private hospitals participated in the
study. Insights around current treatment landscape, epidemiology, clinical
characteristics, future treatment paradigm and Unmet needs.
PSC Market Forecast: Patient
Based Forecast Model (MS. Excel Based Automated Dashboard) which Data
Inputs with sourcing, Market Event and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden and pricing scenario, Summary and Insights.
S. No Asset Company Partner Phase
1 Cilofexor Gilead Sciences, Inc. Phenex Pharmaceuticals III
2 Entyvio Takeda Pharmaceutical Company Ltd Roche III
3 HTD1801 Shenzhen HighTide Biopharmaceutical
Ltd N/A II
4 Maralixibat Mirum Pharmaceuticals Inc. Takeda II
5 NGM282 NGM Biopharmaceuticals, Inc. N/A II
6 Ocaliva Intercept Pharmaceuticals, Inc. Sumitomo Dainippon Pharma II
7 Orbcel Orbsen Therapeutics Ltd. N/A I/II
8 Seladelpar CymaBay Therapeutics, Inc. Johnson & Johnson IND
9 IMU-838 Immunic, Inc. 4SC Investigator Initiated
10 Norursodeoxycholic Acid Dr. Falk Pharma GmbH EA Pharma
Development Outside U.S.
11 CM-101 ChemomAb Ltd. N/A Preclinical
12 EMT inhibitor Pliant Therapeutics N/A Preclinical
13 IDN-7314 Conatus Pharmaceuticals, Inc. N/A Preclinical
14 PLN-74809 Pliant Therapeutics N/A Preclinical
15 SC404 Micelle Biopharma, Inc. N/A Preclinical
16 STP705 Sirnaomics, Inc. Guangdong Xiangxue Preclinicala
No comments:
Post a Comment